In vitro accumulation of technetium-99m-sestamibi in human parathyroid mitochondria

Area of Science:

• Nuclear Medicine
• Biochemistry
• Endocrinology

Background:

• Technetium-99m-sestamibi (sestamibi) is the standard imaging agent for preoperative parathyroid localization.
• The precise mechanism of sestamibi retention in enlarged parathyroid glands in hyperparathyroidism remains unclear.
• Understanding sestamibi uptake is vital for improving diagnostic accuracy in hyperparathyroidism.

Purpose of the Study:

• To investigate the subcellular localization of sestamibi uptake in human parathyroid tissue.
• To elucidate the mechanism of sestamibi retention in the context of hyperparathyroidism.

Main Methods:

• Analysis of freshly harvested and cryopreserved parathyroid glands from hyperparathyroid patients.
• Incubation with sestamibi followed by differential centrifugation to isolate mitochondria.
• Quantification of mitochondrial integrity using succinate dehydrogenase and assessment of sestamibi release with CCCP.

Main Results:

• Over 92% of sestamibi activity was localized to mitochondria in parathyroid tissue.
• Mitochondrial uncoupler CCCP significantly reduced sestamibi in both fresh (84.96%) and cryopreserved tissues.
• Cryopreserved tissue showed reduced mitochondrial sestamibi, similar to CCCP-treated fresh tissue.

Conclusions:

• Mitochondrial activity is the primary determinant of sestamibi uptake in human parathyroid tissue during hyperparathyroidism.
• This finding supports the role of mitochondrial function in sestamibi retention for parathyroid imaging.
• The mechanism is linked to mitochondrial metabolic activity rather than gland size.